We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.125 | 0.69% | 18.125 | 17.75 | 18.50 | 18.125 | 18.00 | 18.00 | 125,995 | 13:24:52 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.38 | 16.52M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/4/2017 13:18 | Darkinbad - Thank for the compliment. However, I haven't pulled everything together in one article, I would need a lot of tree's or a few GIGABITS to pull that off. The article focussed on strategy, Slimbiome and LP-LDL. I suspect Sweetbiotix will be next platform to focus. SOH is on record suggesting OPTI as a group may look to acquire to add to their portfolio of strains. Will this be a company or another opportune acquisition like UoM SKIN IP? The latter I suspect and quite possibly in cognitive health. | elrico | |
21/4/2017 13:02 | SOH mentions cognitive health in the first minute of this recent interview:hTTp://www | parob | |
21/4/2017 12:53 | Elrico, great article as always. It's really good to have everything pulled together in one place and to be reminded of the robust business model that is being established. In any of your discussions with SOH has he indicated at all whether he would consider purchasing new IP in the microbiome field, should an attractive opportunity arise, or is he 100% focused on commercializing the existing IP first? | darkinbad | |
21/4/2017 12:46 | I'll be going along now. | lodger | |
21/4/2017 12:19 | This is a reminder to let you know that we are hosting an investor briefing for OptiBiotix next week. Stephen O’Hara will outline the Company's strategy to deliver value for shareholders and give an update for the year. He will also provide an update on the recent IPO of SkinBioTherapeutics. In attendance with Stephen will be Christina Wood, Director of Sales & Marketing and Per Rehne, Commerical Director. This will be followed by light refreshments and an opportunity to network. The details are below. Please reply to this email if you would like to come along. If you have already let me know you’re coming, there’s no need to respond. | elrico | |
21/4/2017 12:18 | While the diet drink headlines are grabbing and very concerning, not least because I think both strokes and dementia are worse than diabetes risks, I don't see Sweetbiotix getting into bed with unhealthy brands. My view is performance, healthy branded drinks and drinks that are branded as healthy childrens alternative drinks, which we know have very high levels of bad sugars. | elrico | |
21/4/2017 11:40 | That is impressive growth elrico, thanks for clarifying earlier comments | whl2 | |
21/4/2017 11:30 | The 1300 figure is SOH figure not mine. It's no typo either! Like I said, I used my March figure of 800 retail outlet as I didn't think it would have changed that much in a month, but SOH corrected me. Some of these will be small fry selling on eBay and Amazon...in fact, probably most of them are. I have been trying to get Max of GoFigure to add some details to see if I can get an angle on how many customers, retailers are go-it-alone Amazon and eBay retailer listings. I suspect a very high proportion are lone retailers and not Rivital, Whole Foods, or recent Icelandic chains, etc, otherwise we would have heard about them. So while there appears to be a 500+ jump I am not that excited about just yet. I'll save it until Tata Chemicals launch. | elrico | |
21/4/2017 11:24 | Artificial sweeteners give you strokes and dementia. Time for OPTI's natural alternative sugars. | someuwin | |
21/4/2017 10:37 | O/T I know some peeps on this thread have talked about MTFB before - but after its good news on Tuesday it really does look like a no-brainer to me now... Motif Bio (LSE:MTFB, NASDAQ:MTFB) - Superbug busting NEW antibiotic. Successfully passed Phase 3 trial on Tuesday. One more Phase 3 trial underway. This second trial is identical to the 1st one so outcome should be the same - results H2 this year. Then New Drug Application and Marketing Authorisation Application to FDA in USA and EMA in Europe. Approval (expected before end 2018) will lead to expected sales of $1billion per year. Very late stage biotech opportunity. Very much de-risked. Only £80m valuation. Should multi-bag for anyone who can hold for a year or two. | someuwin | |
21/4/2017 10:01 | The report says that "GoFigure is reported to have more than 1300 retail listings" But perhaps that is the number of individual product lines available multiplied by the number of stores they are available in? | someuwin | |
21/4/2017 09:41 | Lukead point one "I don't know if he is dyslexic" and that's why you should think before you post. point two "Me and Elrico are just fine" i think not reading Elricos answer to you below point three you should apologize yet in two of your follow up posts you suggest that Elrico should be actually thanking you. elrico - 20 Apr 2017 - 19:32:24 - 22440 of 22473 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI Luke - It is inconsiderate people like you I wonder WHY I bother. SOH FACT checked it, he was not asked to bloody proof it. People that know me will know why I miss certain typos and grammar even when put through a checker. I don't expect you to understand. It is a free research article I enjoy compiling. The next one will most likely be email only. Hopefully, you don't slip through the net. The links do work. | scotty1 | |
21/4/2017 09:39 | Looks like there is the possibility that someone is still selling in 10k blocks Fools | judijudi | |
21/4/2017 09:21 | Scotty, go eat your morning porridge, if I get things wrong on a bb, it hardly matters, I type things quickly on my I phone and hit the wrong letter, so what, you are an opinionated so and so who likes to have the last word. Me and Elrico are just fine, I don't know if he is dyslexic , but as I have already said just pointed out a couple of things to a first class report , he has since amended. Trust you to bring it up again, must be that grudge I can see on your back lol | lukead | |
21/4/2017 09:21 | I think it's 130 going on the numbers given in the report - hope I'm wrong though! | whl2 | |
21/4/2017 09:13 | I'm amazed that GoFigure products are now available in 1300 retail outlets - am I reading that right? | someuwin | |
21/4/2017 09:12 | https://www.google.c | adnanwolf | |
21/4/2017 08:40 | Great report there Elrico,keep up the excellent work and please don't be put off with posters the likes of Lukead with stupid insensitive posts when he knows nothing of your personal circumstances and to cap it all most of his posts don't come across in good English as JJ pointed out with one y'day. | scotty1 | |
21/4/2017 08:25 | Another superbly comprehensive report by Elrico - great read and good to see that we may be ahead on the Sugars (info I don't remember seeing in the public domain beforehand).Many thanks for your hard work : )CheersSienna | siennadelekat21 | |
21/4/2017 08:23 | Chart-wise, the aim today is to stay above the body of yesterday's doji. So far, so good. M | marnewton | |
21/4/2017 08:05 | J J AND SCOTTY1, good, good, good, good news coming very soon, and I did say that I thought the share price would fall after the split, and yes I did Hoover up some more shares just in case the free skin share had a set date? But look back and you will see I said that I thought the share price would fall, but don't worry we will soon be back and looking up, and I will Hoover up a lot more at this price DIAMOND. | diamond fibre | |
21/4/2017 07:34 | I remember, elrico, because it was a screaming chart sell, with negative divergences all over the shop. That's the trouble with mixing fundamentals with charts, you stop trading what you see. Imminent news and freebie shares in SBTX kept me long. The story here seems quite compelling, so, having traded out last summer I'm holding and buying for the longer haul. Though I reserve the right to change my mind;¬) M Oh...and thanks for the report!¬) | marnewton | |
21/4/2017 06:37 | Bran - Are you confusing my 130p SB target at which I plan to take profits with a YE target? Let me ask you what are you base your 130p in 8 months on? If I was to offer any kind of a target outside on a public forum (outside of fun) I would attempt to qualify it and cover my back with a caveat or two. Targets have a nasty habit of making even the experienced look foolish. I recently suggested 90p by LP-LDL launch, I was within a gnats chuff of it only for it to reverse. I now look an idiot. Nobody will remember it hit 90p intraday. | elrico | |
21/4/2017 00:44 | Elrico in your opinion is it realistic to aim for a share price of £1.30 by year end? That is my target. | branboyd1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions